Is Vyvanse (lisdexamfetamine) appropriate or safe for use in patients with Alzheimer’s disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Vyvanse (Lisdexamfetamine) in Alzheimer's Disease

Vyvanse is not appropriate for use in Alzheimer's disease and should be avoided. There is no evidence supporting its efficacy for cognitive or behavioral symptoms of dementia, and it carries significant cardiovascular and psychiatric risks that are particularly dangerous in this vulnerable population.

Why Vyvanse Should Not Be Used

Lack of Evidence for Efficacy

  • Psychostimulants as a class show no meaningful benefit for cognition in dementia. A systematic review found that psychostimulants had "little to no effect on cognition" in patients with dementia 1.
  • While methylphenidate (a different stimulant) showed some possible benefit for apathy specifically, the evidence remains limited and does not extend to lisdexamfetamine 1.
  • Vyvanse has never been studied or approved for any dementia-related indication—its only FDA-approved uses are ADHD and binge eating disorder 2.

Serious Safety Concerns in Older Adults with Dementia

Cardiovascular risks are particularly dangerous:

  • The FDA label explicitly warns of sudden death in patients with serious heart disease, along with increased blood pressure and heart rate 2.
  • Older adults with dementia frequently have underlying cardiovascular disease, making them especially vulnerable to these effects 2.

Psychiatric complications are highly problematic:

  • Vyvanse can cause or worsen psychotic symptoms (hallucinations, delusions), mania, agitation, and behavioral disturbances 2.
  • These are the exact symptoms that often require treatment in dementia patients—using Vyvanse would risk making them worse 2.

Additional concerns specific to dementia populations:

  • The drug can suppress appetite and cause weight loss 2, which is particularly harmful in dementia patients who already struggle with maintaining adequate nutrition.
  • Insomnia is a common side effect 2, and sleep disturbances are already prevalent and problematic in Alzheimer's disease.

What Should Be Used Instead

For Cognitive Symptoms

Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine remain the evidence-based standard treatments for mild to moderate Alzheimer's disease 3, 4.

  • These provide modest but meaningful improvements in cognition, function, and global assessment 4.
  • They should be continued unless specific criteria for discontinuation are met (meaningful worsening despite treatment, intolerable side effects, severe/end-stage dementia, or poor adherence) 3.

For Apathy (If That Is the Target Symptom)

If apathy is the specific concern prompting consideration of a stimulant:

  • Methylphenidate has limited evidence as a possible treatment for apathy in dementia, but patient selection must be extremely careful 1.
  • Screen rigorously for cardiovascular disease, psychotic symptoms, and agitation before considering any stimulant 1.
  • Lisdexamfetamine specifically has no data supporting its use for this indication and should not be substituted for methylphenidate 1.

For Behavioral Symptoms

  • Non-pharmacologic interventions should be the first-line approach 5.
  • If pharmacotherapy is necessary for dangerous agitation or psychosis, antipsychotics may be considered with careful risk-benefit assessment and informed consent 5.
  • Brexpiprazole is now FDA-approved specifically for agitation associated with Alzheimer's disease 6.

Critical Clinical Pitfall

Do not assume that because Vyvanse is a "cognitive enhancer" for ADHD, it will help cognition in dementia. The pathophysiology of ADHD and Alzheimer's disease are fundamentally different—dopaminergic and noradrenergic augmentation that improves attention in ADHD does not address the cholinergic deficits and neurodegeneration of Alzheimer's disease 7.

Bottom Line

There is no role for Vyvanse in the treatment of Alzheimer's disease. The absence of efficacy data combined with serious cardiovascular and psychiatric risks makes its use inappropriate and potentially harmful in this population 2, 1. Stick with evidence-based dementia treatments: cholinesterase inhibitors and memantine for cognitive symptoms, and guideline-directed approaches for behavioral symptoms 3, 4, 5.

References

1
Research

Use of psychostimulants in patients with dementia.

The Annals of pharmacotherapy, 2010

6
Research

Treatment of Alzheimer Disease.

Continuum (Minneapolis, Minn.), 2024

Related Questions

Does Vyvanse (lisdexamfetamine) cause cognitive decline or increase the risk of Alzheimer's disease in a person with a family history of Alzheimer's?
Why would you initiate memantine in a primary‑care patient with moderate‑to‑severe Alzheimer’s disease?
How should memantine be initiated in an older patient with moderate-to-severe Alzheimer disease, including dosing schedule and renal function adjustments?
What are the FDA‑approved pharmacologic treatments for Alzheimer’s disease?
Can a 50-year-old woman on levothyroxine 50 µg who has stress‑triggered premature ventricular contractions start lisdexamfetamine (Vyvanse) 20 mg?
Can atorvastatin cause memory impairment, and should the medication be paused or switched to an alternative statin?
What is the appropriate duration of antibiotic therapy for preseptal cellulitis?
Can total parenteral nutrition (TPN) and Lactated Ringer's solution be administered simultaneously?
Can total parenteral nutrition be infused through a central line lumen while lactated Ringer’s solution is infused through a separate lumen of the same catheter?
What is the appropriate isotretinoin (Accutane) dose for a 75‑kg patient?
Is a serum potassium of 6.3 mEq/L classified as severe hyperkalemia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.